These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 34997307)
1. Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism. de la Nuez Veulens A; Ginarte YMÁ; Fernandez RER; Leclerc F; Cabrera LAM J Mol Model; 2022 Jan; 28(2):31. PubMed ID: 34997307 [TBL] [Abstract][Full Text] [Related]
2. Ligand recognition properties of the vasopressin V2 receptor studied under QSAR and molecular modeling strategies. Martínez-Archundia M; Colín-Astudillo B; Moreno-Vargas LM; Ramírez-Galicia G; Garduño-Juárez R; Deeb O; Contreras-Romo MC; Quintanar-Stephano A; Abarca-Rojano E; Correa-Basurto J Chem Biol Drug Des; 2017 Nov; 90(5):840-853. PubMed ID: 28419717 [TBL] [Abstract][Full Text] [Related]
3. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system. Slusarz MJ; Slusarz R; Ciarkowski J Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859 [TBL] [Abstract][Full Text] [Related]
4. A Three-Site Mechanism for Agonist/Antagonist Selective Binding to Vasopressin Receptors. Saleh N; Saladino G; Gervasio FL; Haensele E; Banting L; Whitley DC; Sopkova-de Oliveira Santos J; Bureau R; Clark T Angew Chem Int Ed Engl; 2016 Jul; 55(28):8008-12. PubMed ID: 27184628 [TBL] [Abstract][Full Text] [Related]
5. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems. Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100 [TBL] [Abstract][Full Text] [Related]
6. Molecular modeling of interactions of the non-peptide antagonist YM087 with the human vasopressin V1a, V2 receptors and with oxytocin receptors. Giełdoń A; Kaźmierkiewicz R; Slusarz R; Ciarkowski J J Comput Aided Mol Des; 2001 Dec; 15(12):1085-104. PubMed ID: 12160092 [TBL] [Abstract][Full Text] [Related]
14. Exploring the ligand recognition properties of the human vasopressin V1a receptor using QSAR and molecular modeling studies. Contreras-Romo MC; Martínez-Archundia M; Deeb O; Slusarz MJ; Ramírez-Salinas G; Garduño-Juárez R; Quintanar-Stephano A; Ramírez-Galicia G; Correa-Basurto J Chem Biol Drug Des; 2014 Feb; 83(2):207-23. PubMed ID: 24010681 [TBL] [Abstract][Full Text] [Related]
15. Position three in vasopressin antagonist tolerates conformationally restricted and aromatic amino acid substitutions: a striking contrast with vasopressin agonists. Manning M; Cheng LL; Stoev S; Klis W; Nawrocka E; Olma A; Sawyer WH; Wo NC; Chan WY J Pept Sci; 1997; 3(1):31-46. PubMed ID: 9230469 [TBL] [Abstract][Full Text] [Related]
16. Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling. Postina R; Kojro E; Fahrenholz F Adv Exp Med Biol; 1998; 449():371-85. PubMed ID: 10026828 [TBL] [Abstract][Full Text] [Related]
17. Molecular dynamics of a vasopressin V2 receptor in a phospholipid bilayer membrane. Czaplewski C; Pasenkiewicz-Gierula M; Ciarkowski J J Recept Signal Transduct Res; 1999; 19(1-4):355-67. PubMed ID: 10071770 [TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulation of human neurohypophyseal hormone receptors complexed with oxytocin-modeling of an activated state. Slusarz MJ; Slusarz R; Ciarkowski J J Pept Sci; 2006 Mar; 12(3):171-9. PubMed ID: 16114099 [TBL] [Abstract][Full Text] [Related]
19. Calmodulin interacts with the V2 vasopressin receptor: elimination of binding to the C terminus also eliminates arginine vasopressin-stimulated elevation of intracellular calcium. Nickols HH; Shah VN; Chazin WJ; Limbird LE J Biol Chem; 2004 Nov; 279(45):46969-80. PubMed ID: 15319442 [TBL] [Abstract][Full Text] [Related]
20. A computational strategy to understand structure-activity relationship of 1,3-disubstituted imidazole [1,5-α] pyrazine derivatives described as ATP competitive inhibitors of the IGF-1 receptor related to Ewing sarcoma. Guaitoli V; Alvarez-Ginarte YM; Montero-Cabrera LA; Bencomo-Martínez A; Badel YP; Giorgetti A; Suku E J Mol Model; 2020 Aug; 26(8):222. PubMed ID: 32748063 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]